Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed Fund to be listed on public markets in due course […]